Basic Study
Copyright ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2016; 22(42): 9346-9355
Published online Nov 14, 2016. doi: 10.3748/wjg.v22.i42.9346
Genetic polymorphism in CD14 gene, a co-receptor of TLR4 associated with non-alcoholic fatty liver disease
Shweta Kapil, Ajay Duseja, Bal Krishan Sharma, Bhupesh Singla, Anuradha Chakraborti, Ashim Das, Pallab Ray, Radha K Dhiman, Yogesh Chawla
Shweta Kapil, Ajay Duseja, Bal Krishan Sharma, Bhupesh Singla, Radha K Dhiman, Yogesh Chawla, Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Anuradha Chakraborti, Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Ashim Das, Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Pallab Ray, Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
Author contributions: Kapil S and Duseja A conceived the study, performed all analyses, interpreted data, and prepared the manuscript; Kapil S performed all molecular biological tests; Sharma BK and Singla B assisted with the collection of samples and sequencing data analysis; Chakraborti A and Ray P helped interpret the data and assisted in preparing the manuscript; Das A performed all histological analyses and reviewed the manuscript; Dhiman RK and Chawla Y participated in the study’s design and critically reviewed the manuscript.
Supported by Indian Council of Medical Research (ICMR), New Delhi, No. 5/4/3-7/2009-NCD-II.
Institutional review board statement: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional (PGIMER, Chandigarh) and/or national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by the ethical committee of PGIMER, Chandigarh (Ethics committee No. 7923-1Trg-08/2281 dated 21/1/10).
Informed consent statement: Informed consent was obtained from all individual participants included in the study.
Conflict-of-interest statement: All authors have no conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Dr. Ajay Duseja, MD, DM, MNAMS, FACG, Department of Hepatology, Postgraduate Institute of Medical Education and Research (PGIMER), Sector-12, Chandigarh 160012, India. ajayduseja@yahoo.co.in
Telephone: +91-172-2756336 Fax: +91-172-2744401
Received: March 31, 2016
Peer-review started: April 6, 2016
First decision: May 30, 2016
Revised: August 3, 2016
Accepted: September 14, 2016
Article in press: September 14, 2016
Published online: November 14, 2016
Processing time: 226 Days and 5.8 Hours
Core Tip

Core tip: Our study demonstrated that non-alcoholic fatty liver disease (NAFLD) patients with TT genotype of C (-159) T polymorphism in cluster of differentiation 14 promoter gene have a higher risk of NAFLD development. However, this polymorphism did not affect liver disease severity. We found no association of toll-like receptor (TLR) 2 ARG753, TLR4 (Asp299Gly), TLR4 (Thr399Ile), and CD 14 C/T 550 polymorphisms with the risk of NAFLD development.